Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8

NCT07434713 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT07434713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07434713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Recruiting
Start date
July 14, 2025
Completion date
March 27, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd)